Brucke Financial Inc. Buys Shares of 6,420 Novo Nordisk A/S (NYSE:NVO)

Brucke Financial Inc. bought a new position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 6,420 shares of the company's stock, valued at approximately $542,000.

A number of other institutional investors and hedge funds also recently modified their holdings of NVO. GQG Partners LLC increased its position in Novo Nordisk A/S by 74.7% in the fourth quarter. GQG Partners LLC now owns 12,994,533 shares of the company's stock worth $1,117,790,000 after buying an additional 5,556,460 shares during the period. Raymond James Financial Inc. bought a new position in shares of Novo Nordisk A/S during the fourth quarter worth about $404,910,000. Loomis Sayles & Co. L P increased its holdings in shares of Novo Nordisk A/S by 34.2% in the 4th quarter. Loomis Sayles & Co. L P now owns 11,571,686 shares of the company's stock worth $995,397,000 after acquiring an additional 2,947,771 shares during the period. Nuveen Asset Management LLC lifted its position in Novo Nordisk A/S by 73.2% in the 4th quarter. Nuveen Asset Management LLC now owns 6,244,931 shares of the company's stock valued at $537,189,000 after purchasing an additional 2,639,693 shares during the last quarter. Finally, Two Sigma Investments LP acquired a new position in Novo Nordisk A/S during the 4th quarter valued at about $158,657,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have commented on NVO shares. Morgan Stanley began coverage on shares of Novo Nordisk A/S in a research note on Wednesday, February 12th. They issued an "equal weight" rating on the stock. Kepler Capital Markets upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. BNP Paribas assumed coverage on Novo Nordisk A/S in a research note on Tuesday, April 15th. They set an "underperform" rating on the stock. Guggenheim cut Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research note on Thursday, April 17th. Finally, Wall Street Zen raised Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a report on Friday, April 25th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $135.00.

Novo Nordisk A/S Price Performance

NVO stock traded up $3.04 on Tuesday, hitting $70.39. 9,168,584 shares of the company's stock traded hands, compared to its average volume of 6,711,485. The stock has a market cap of $315.88 billion, a price-to-earnings ratio of 21.40, a P/E/G ratio of 0.90 and a beta of 0.65. Novo Nordisk A/S has a 1-year low of $57.00 and a 1-year high of $148.15. The stock has a fifty day moving average of $66.07 and a 200-day moving average of $82.47. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, hitting the consensus estimate of $0.92. The business had revenue of $11.87 billion for the quarter. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.